Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer

Overview

Journal Cancer Res

Specialty Oncology

Date 2017 Nov 4

PMID 29097609

Citations 33

Authors

Christopher C Mills

E A Kolb

Valerie B Sampson

Affiliations

Soon will be listed here.

Abstract

This review describes the pivotal roles of cell-cycle and checkpoint regulators and discusses development of specific cell-cycle inhibitors for therapeutic use for pediatric cancer. The mechanism of action as well as the safety and tolerability of drugs in pediatric patients, including compounds that target CDK4/CDK6 (palbociclib, ribociclib, and abemaciclib), aurora kinases (AT9283 and MLN8237), Wee1 kinase (MK-1775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented. The design of mechanism-based combinations that exploit the cross-talk of signals activated by cell-cycle arrest, as well as pediatric-focused drug development, are critical for the advancement of drugs for rare childhood diseases. .

Citing Articles

Reversible and effective cell cycle synchronization method for studying stage-specific processes.

Chen Y, Reddy S, Suzuki A Life Sci Alliance. 2025; 8(5).

PMID: 40037894 PMC: 11880160. DOI: 10.26508/lsa.202403000.

Reversible and effective cell cycle synchronization method for studying stage-specific investigations.

Chen Y, Reddy S, Suzuki A bioRxiv. 2024; .

PMID: 39282459 PMC: 11398389. DOI: 10.1101/2024.09.02.610832.

Anti-tumor effect and hepatotoxicity mechanisms of psoralen.

Meng D, Dong Y, Shang Q, Sun Z Front Pharmacol. 2024; 15:1442700.

PMID: 39161897 PMC: 11331265. DOI: 10.3389/fphar.2024.1442700.

AVEN: a novel oncogenic biomarker with prognostic significance and implications of AVEN-associated immunophenotypes in lung adenocarcinoma.

Fan D, Yang M, Lee H, Lee J, Kim H Front Mol Biosci. 2023; 10:1265359.

PMID: 37908231 PMC: 10613694. DOI: 10.3389/fmolb.2023.1265359.

KIF11 serves as a cell cycle mediator in childhood acute lymphoblastic leukemia.

Zhu L, Chen C, Kang M, Ma X, Sun X, Xue Y J Cancer Res Clin Oncol. 2023; 149(17):15609-15622.

PMID: 37656243 PMC: 10620298. DOI: 10.1007/s00432-023-05240-w.

References

Horton T, Ames M, Reid J, Krailo M, Pendergrass T, Mosher R . A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study. Pediatr Blood Cancer. 2007; 50(4):788-92. PMC: 6777707. DOI: 10.1002/pbc.21310. View

Zhao Y, Zhang Y, Yang Z, Li A, Dong J . Simultaneous knockdown of BRAF and expression of INK4A in melanoma cells leads to potent growth inhibition and apoptosis. Biochem Biophys Res Commun. 2008; 370(3):509-13. DOI: 10.1016/j.bbrc.2008.03.148. View

Caretti V, Hiddingh L, Lagerweij T, Schellen P, Koken P, Hulleman E . WEE1 kinase inhibition enhances the radiation response of diffuse intrinsic pontine gliomas. Mol Cancer Ther. 2012; 12(2):141-50. DOI: 10.1158/1535-7163.MCT-12-0735. View

Tibes R, Bogenberger J, Chaudhuri L, Hagelstrom R, Chow D, Buechel M . RNAi screening of the kinome with cytarabine in leukemias. Blood. 2012; 119(12):2863-72. PMC: 8221104. DOI: 10.1182/blood-2011-07-367557. View

Muscal J, Scorsone K, Zhang L, Ecsedy J, Berg S . Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs. 2012; 31(1):39-45. PMC: 3655801. DOI: 10.1007/s10637-012-9831-9. View

Malumbres M . Cyclin-dependent kinases. Genome Biol. 2014; 15(6):122. PMC: 4097832. DOI: 10.1186/gb4184. View

Qi W, Zhang W, Edwards H, Chu R, Madlambayan G, Taub J . Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biol Ther. 2015; 16(12):1784-93. PMC: 4847803. DOI: 10.1080/15384047.2015.1095406. View

Kelly K, Nawrocki S, Espitia C, Zhang M, Yang J, Padmanabhan S . Targeting Aurora A kinase activity with the investigational agent alisertib increases the efficacy of cytarabine through a FOXO-dependent mechanism. Int J Cancer. 2012; 131(11):2693-703. PMC: 3419336. DOI: 10.1002/ijc.27579. View

Maris J, Morton C, Gorlick R, Kolb E, Lock R, Carol H . Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer. 2010; 55(1):26-34. PMC: 2874079. DOI: 10.1002/pbc.22430. View

10.

Pikman Y, Alexe G, Roti G, Conway A, Furman A, Lee E . Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2017; 23(4):1012-1024. PMC: 5432118. DOI: 10.1158/1078-0432.CCR-15-2869. View

11.

Quartuccio S, Schindler K . Functions of Aurora kinase C in meiosis and cancer. Front Cell Dev Biol. 2015; 3:50. PMC: 4542505. DOI: 10.3389/fcell.2015.00050. View

12.

Chandrasekaran G, Tatrai P, Gergely F . Hitting the brakes: targeting microtubule motors in cancer. Br J Cancer. 2015; 113(5):693-8. PMC: 4559828. DOI: 10.1038/bjc.2015.264. View

13.

Do K, Wilsker D, Ji J, Zlott J, Freshwater T, Kinders R . Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors. J Clin Oncol. 2015; 33(30):3409-15. PMC: 4606059. DOI: 10.1200/JCO.2014.60.4009. View

14.

Sells T, Chau R, Ecsedy J, Gershman R, Hoar K, Huck J . MLN8054 and Alisertib (MLN8237): Discovery of Selective Oral Aurora A Inhibitors. ACS Med Chem Lett. 2015; 6(6):630-4. PMC: 4468408. DOI: 10.1021/ml500409n. View

15.

Hutcheson J, Witkiewicz A, Knudsen E . The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle. 2015; 14(24):3812-9. PMC: 4825764. DOI: 10.1080/15384101.2015.1010922. View

16.

Bretones G, Delgado M, Leon J . Myc and cell cycle control. Biochim Biophys Acta. 2014; 1849(5):506-16. DOI: 10.1016/j.bbagrm.2014.03.013. View

17.

Rugo H, Rumble R, Macrae E, Barton D, Connolly H, Dickler M . Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016; 34(25):3069-103. DOI: 10.1200/JCO.2016.67.1487. View

18.

Krajewska M, Heijink A, Bisselink Y, Seinstra R, Sillje H, de Vries E . Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination. Oncogene. 2012; 32(24):3001-8. DOI: 10.1038/onc.2012.296. View

19.

Kelleher F, OSullivan H . FOXM1 in sarcoma: role in cell cycle, pluripotency genes and stem cell pathways. Oncotarget. 2016; 7(27):42792-42804. PMC: 5173172. DOI: 10.18632/oncotarget.8669. View

20.

Kavallaris M . Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer. 2010; 10(3):194-204. DOI: 10.1038/nrc2803. View